ClinicalTrials.gg
RecruitingNCT04179929Updated Feb 18, 2022

Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

An interventional study of Pediatric-type of chemotherapy and allogeneic HSCT in Acute Lymphoblastic Leukemia, sponsored by PETHEMA Foundation. Recruiting at 108 sites in Spain. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by PETHEMA Foundation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation — 3 open to participants now, 3 under way, none of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · PETHEMA Foundation.

Planned enrollment
3rd of 16
300 · median 100
Started
2019
the only one that year
No phase
3 of 19
2 open now
Registered
17th of 19
by date

Among the 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation, this one is the 3rd largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2019, is one of 3 with no phase, and was the 17th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

3 of the 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by PETHEMA Foundation, or all of them as a file.
02

Study summary

After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

Read the detailed description

Patients will be uniformly treated with four drug-induction: vincristine (VCR), prednisone (PDN), pegylated asparaginase (PegASP), daunorubicin (DNR).

Resistant patients will receive a second induction with fludarabine, Ara-C, G-Colony-Stimulating Factor (G-CSF) and idarubicin (FLAG-IDA).

Patients with adequate MRD clearance after induction will receive 3 blocks of early consolidation. If adequate MRD clearance and good genetic background, the patients will proceed to delayed intensification, reinduction and maintenance. The remaining patients will receive early or delayed alloHSCT.

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • ALL
  • adult
  • Ph-negative
  • minimal residual disease
  • transplantation
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients 18-60 yr with de novo Ph-neg ALL
  • (ECOG) 0-2 (or >2 if due to ALL)

Exclusion criteria

Exclusion Criteria:

  • Mature B-ALL, Ph+ ALL or blast crisis of chronic myeloid leukemia (CML), ALL of ambiguous lineage
  • >2 not due to ALL
  • Impaired cardiac, respiratory, hepatic or renal function not due to ALL
  • Pregnancy
  • positivity
  • Severe psychiatric disease
  • Negative to sign .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Other
    CHEMOTHERAPY

    Pediatric-type of chemotherapy

    Drug: Pediatric-type of chemotherapy

  • Other
    allogeneic HSCT

    allogeneic HSCT

    Procedure: allogeneic HSCT

Interventions

  • DrugPediatric-type of chemotherapy

    Pediatric type chemotherapy (induction, early and delayed consolidation, reinduction, maintenance). Induction (VCR,PDN,PegASP,DNR). Early and delayed consolidation (high-dose Methotrexate, high-dose Cytarabine, PegASP). Reinduction (VCR, PDN, PegASP, DNR). Maintenance (Methotrexate, Mercaptopurine)

  • Procedureallogeneic HSCT

    allogeneic HSCT

06

What researchers measure

Primary outcomes

  1. Overall survival

    Time from diagnosis to death or last follow-up

    Time frame: 3 years

Secondary outcomes

  1. Complete remission (CR) rate

    Proportion of patients who achieve CR with or 2 induction therapy lines

    Time frame: 4 or 8 weeks after treatment onset

  2. MRD status after induction and consolidation

    Proportion of patients who achieve and maintain the negative MRD status (\<10-4)

    Time frame: After induction (4-8 weeks) and consolidation (16-20 weeks)

Other outcomes

  1. alloSCT realization

    Proportion of patients who receive early or delayed alloHSCT

    Time frame: Early alloHSCT: 15-20 weeks from diagnosis. Delayed: 30-35 weeks from diagnosis.

07

Study locations

23 of 108 sites recruiting
  • Ico-Hugtip
    Badalona, Barcelona 08916, Spain
    Recruiting
  • H Albacete
    Albacete, Spain
    Not yet recruiting
    • José Santiago Bermón · Contact
  • H. General Univ. de Alicante
    Alicante, Spain
    Recruiting
    • Cristina Gil · Contact
  • H. General Univ. de Alicante
    Alicante, Spain
    Not yet recruiting
    • Pascual Fernández Abellán · Contact
  • Clínica Teknon
    Barcelona, Spain
    Not yet recruiting
    • Pilar Vivancos · Contact
  • H del Mar
    Barcelona, Spain
    Not yet recruiting
    • Eva Gimeno · Contact
  • H. Clínic de Barcelona
    Barcelona, Spain
    Recruiting
    • Jordi Esteve · Contact
  • H. del Mar
    Barcelona, Spain
    Not yet recruiting
    • Eugènia Abella Monreal · Contact
  • H. Sant Pau
    Barcelona, Spain
    Recruiting
    • Irene García-Cadenas · Contact
  • H. Vall d'Hebron
    Barcelona, Spain
    Recruiting
    • Pere Barba · Contact
  • H. Vall d'Hebron
    Barcelona, Spain
    Not yet recruiting
    • Pau Abrisqueta · Contact
  • ICO-Duran i Reynals
    Bellvitge, Spain
    Not yet recruiting
    • Santiago Mercadal · Contact
  • H Basurto
    Bilbao, Spain
    Not yet recruiting
    • Olga Arce Fernández · Contact
  • Hu Basurto
    Bilbao, Spain
    Recruiting
    • Cristina Barrenetxea · Contact
  • H. Jerez
    Cadiz, Spain
    Not yet recruiting
    • Carmen Muñoz García · Contact
  • H. Puerta del Mar
    Cadiz, Spain
    Not yet recruiting
    • Victoria Martín Reina · Contact
  • H. General de Castellón
    Castelló, Spain
    Not yet recruiting
    • Raimundo García Boyero · Contact
  • H. San Pedro de Alcántara
    Cáceres, Spain
    Not yet recruiting
    • Juan Bergua · Contact
  • H. Reina Sofía
    Córdoba, Spain
    Not yet recruiting
    • Josefina Serrano López · Contact
  • H. Fuenlabrada
    Fuenlabrada, Spain
    Not yet recruiting
    • Pilar Bravo · Contact
  • H Galdakao
    Galdakao, Spain
    Not yet recruiting
    • Matxalen Olivares · Contact
  • H. Univ. De Getafe
    Getafe, Spain
    Not yet recruiting
    • Carmen Monteserín · Contact
  • ICO-Dr.Josep Trueta
    Girona, Spain
    Recruiting
    • Nazly Santos · Contact
  • H. Guadalajara
    Guadalajara, Spain
    Not yet recruiting
    • Miguel Díaz Morfa · Contact
  • H Juan Ramón Jiménez
    Huelva, Spain
    Not yet recruiting
    • Encarni Gil Espárraga · Contact
  • Complejo Hospitalario Ciudad de Jaén
    Jaén, Spain
    Recruiting
    • Angela Baena · Contact
  • H. Jerez de la Frontera
    Jerez De La Frontera, Spain
    Recruiting
    • Lourdes Hermosín · Contact
  • H. A Coruña
    La Coruña, Spain
    Not yet recruiting
    • Víctor Noriega Concepción · Contact
  • H. General Lanzarote
    Lanzarote, Spain
    Not yet recruiting
    • Azueg Hong · Contact
  • H Dr. Negrín
    Las Palmas De Gran Canaria, Spain
    Recruiting
    • Carlos Rodríguez · Contact
  • Hospital Insular de Gran Canaria
    Las Palmas De Gran Canaria, Spain
    Not yet recruiting
    • Rosa Fernández · Contact
  • Hu Gran Canarias Dr Negrin
    Las Palmas De Gran Canaria, Spain
    Not yet recruiting
    • Carlos Rodríguez Medina · Contact
  • H. Arnau De Vilanova
    Lleida, Spain
    Recruiting
    • Antoni García Guiñón · Contact
  • H. Lucus Augusti
    Lugo, Spain
    Not yet recruiting
    • Esperanza Lavilla · Contact
  • H. Lucus Augusti
    Lugo, Spain
    Not yet recruiting
    • Maria José Sánchez Sánchez · Contact
  • H. Lucus Augusti
    Lugo, Spain
    Not yet recruiting
    • Jesús Arias Sampedro · Contact
  • Fundación Jiménez Díaz
    Madrid, Spain
    Not yet recruiting
    • José Luis López Lorenzo · Contact
  • H La Zarzuela
    Madrid, Spain
    Not yet recruiting
    • Daniel García Belmonte · Contact
  • H Puerta de Hierro
    Madrid, Spain
    Recruiting
    • Irene Romera · Contact
  • H Puerta de Hierro
    Madrid, Spain
    Not yet recruiting
    • Rafael Forés · Contact
  • H. 12 de Octubre
    Madrid, Spain
    Not yet recruiting
    • Carlos Grande · Contact
  • H. 12 de Octubre
    Madrid, Spain
    Not yet recruiting
    • Pilar Martínez Sánchez · Contact
  • H. 12 de Octubre
    Madrid, Spain
    Not yet recruiting
    • José María Sánchez Pina · Contact
  • H. 12 de Octubre
    Madrid, Spain
    Not yet recruiting
    • María Calbacho · Contact
  • H. 12 de Octubre
    Madrid, Spain
    Not yet recruiting
    • Mario Rodríguez Rodríguez · Contact
  • H. Clínico de Madrid
    Madrid, Spain
    Not yet recruiting
    • Eloy del Potro · Contact
  • H. Clínico de Madrid
    Madrid, Spain
    Not yet recruiting
    • Mónica Sánchez · Contact
  • H. Gregorio Marañón
    Madrid, Spain
    Not yet recruiting
    • Silvia Monsalvo · Contact
  • H. Gregorio Marañón
    Madrid, Spain
    Not yet recruiting
    • Mariana Bastos Oreiro · Contact
  • H. Infanta Sofía
    Madrid, Spain
    Not yet recruiting
    • Pilar Massó · Contact
  • H. Madrid-Norte Sanchinarro
    Madrid, Spain
    Recruiting
    • Alfons Serrano · Contact
  • H. Ramón y Cajal
    Madrid, Spain
    Recruiting
    • Alberto González · Contact
  • H. Ramón y Cajal
    Madrid, Spain
    Not yet recruiting
    • Anabelle Chinea · Contact
  • H. Univ La Paz
    Madrid, Spain
    Not yet recruiting
    • Dolores Hernández Maraver · Contact
  • Hu Infanta Leonor
    Madrid, Spain
    Not yet recruiting
    • María José Penalva Moreno · Contact
  • Hu La Princesa
    Madrid, Spain
    Not yet recruiting
    • Reyes Arranz · Contact
  • H. Morales Meseguer
    Murcia, Spain
    Not yet recruiting
    • Maria Luz Amigo Lozano · Contact
  • H. Virgen de la Arrixaca
    Murcia, Spain
    Not yet recruiting
    • José Maria Moraleda · Contact
  • H. Virgen de la Arrixaca
    Murcia, Spain
    Not yet recruiting
    • Andrés Sánchez Salinas · Contact
  • H. Virgen de la Arrixaca
    Murcia, Spain
    Not yet recruiting
    • Maria Carmen Garcia Garay · Contact
  • H. Carlos Haya
    Málaga, Spain
    Not yet recruiting
    • Concha Bethencourt · Contact
  • H. Clínico Univ. Virgen de la Victoria
    Málaga, Spain
    Recruiting
    • MªPaz Queipo de Llano · Contact
  • H. Regional de Málaga
    Málaga, Spain
    Recruiting
    • Alejandro Contento · Contact
  • Complejo Hosp. Univ. de Orense
    Orense, Spain
    Not yet recruiting
    • María Elsa López Ansoar · Contact
  • Complejo Hosp. Univ. de Orense
    Orense, Spain
    Not yet recruiting
    • Manuel Albors Ferreiro · Contact
  • Complejo Hosp. Univ. de Orense
    Orense, Spain
    Not yet recruiting
    • Marta Rodríguez · Contact
  • Complejo Hosp. Univ. de Orense
    Orense, Spain
    Not yet recruiting
    • José Angel Méndez Sánchez · Contact
  • H. Central de Asturias
    Oviedo, Spain
    Recruiting
    • Teresa Bernal · Contact
  • H Río Carrión
    Palencia, Spain
    Not yet recruiting
    • José María Alonso Alonso · Contact
  • H. Son Espases
    Palma De Mallorca, Spain
    Recruiting
    • Andrés Novo · Contact
  • H. Son Llàtzer
    Palma De Mallorca, Spain
    Not yet recruiting
    • Antònia Cladera · Contact
  • Complejo Hospitalario Navarra
    Pamplona, Spain
    Recruiting
    • M Carmen Mateos · Contact
  • H. Clínico Univ. de Navarra
    Pamplona, Spain
    Not yet recruiting
    • José Rifón · Contact
  • H. Virgen del Camino
    Pamplona, Spain
    Not yet recruiting
    • Maria Carmen Mateos Rodríguez · Contact
  • Complejo Hospitalario Pontevedra - Hospital Montecelo
    Pontevedra, Spain
    Not yet recruiting
    • Maria Lourdes Amador · Contact
  • H. Parc Taulí
    Sabadell, Spain
    Not yet recruiting
    • Sonia Piernas · Contact
  • H. Clínico Univ. de Salamanca
    Salamanca, Spain
    Not yet recruiting
    • Mónica Cabrero · Contact
  • H. Clínico Univ. de Salamanca
    Salamanca, Spain
    Not yet recruiting
    • Jesús Mª Hernández Rivas · Contact
  • H Donostia
    San Sebastián, Spain
    Not yet recruiting
    • Maria Teresa Artola · Contact
  • H Donostia
    San Sebastián, Spain
    Not yet recruiting
    • Nerea Caminos Uresandi · Contact
  • H Donostia
    San Sebastián, Spain
    Not yet recruiting
    • Izaskun Ceberio · Contact
  • H Donostia
    San Sebastián, Spain
    Not yet recruiting
    • Maialen Sirvent Auzmendi · Contact
  • H. Univ. de Canarias
    Santa Cruz De Tenerife, Spain
    Not yet recruiting
    • Beatriz Soria Santa Bárbara · Contact
  • H. Marqués de Valdecilla
    Santander, Spain
    Not yet recruiting
    • Mercedes Colorado · Contact
  • H. Marqués de Valdecilla
    Santander, Spain
    Not yet recruiting
    • Arancha Bermúdez · Contact
  • Complejo Hosp. Univ. Santiago de Compostela
    Santiago De Compostela, Spain
    Not yet recruiting
    • Maria José Rabuñal Martínez · Contact
  • Complejo Hosp. Univ. Santiago de Compostela
    Santiago De Compostela, Spain
    Recruiting
    • Natalia Alonso · Contact
  • H. General de Segovia
    Segovia, Spain
    Not yet recruiting
    • José Antonio Queizán Hernández · Contact
  • H. Universitario de Valme
    Sevilla, Spain
    Not yet recruiting
    • Carmen Couto · Contact
  • H. Virgen del Rocío
    Sevilla, Spain
    Recruiting
    • José González Campos · Contact
  • ICO-Joan XXIII
    Tarragona, Spain
    Not yet recruiting
    • Marta Cervera · Contact
  • Mútua de Terrassa
    Terrassa, Spain
    Not yet recruiting
    • Ferran Vall-Llovera Calmet · Contact
  • H Torrejón
    Torrejón De Ardoz, Spain
    Not yet recruiting
    • Ana Sebrango Sadia · Contact
  • H. Verge de la Cinta
    Tortosa, Spain
    Not yet recruiting
    • Xavier Ortin Font · Contact
  • H. Arnau de Vilanova
    Valencia, Spain
    Not yet recruiting
    • Aurelio López · Contact
  • H. Clínico Univ. de Valencia
    Valencia, Spain
    Not yet recruiting
    • Mar Tormo · Contact
  • H. Dr. Peset
    Valencia, Spain
    Not yet recruiting
    • María José Sayas · Contact
  • H. Dr. Peset
    Valencia, Spain
    Not yet recruiting
    • María Pedreño · Contact
  • H. General Univ. de Valencia
    Valencia, Spain
    Not yet recruiting
    • Magdalena Sánchez · Contact
  • H. la Fe
    Valencia, Spain
    Recruiting
    • Pau Montesinos · Contact

Showing the first 100 of 108 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2019 (actual). Primary completion is estimated for Nov 2026, 84 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 84 months is above that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2019
First posted
Nov 27, 2019
StartActual
Nov 25, 2019
Primary completionEst.
Nov 2026
CompletionEst.
Feb 2027
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04179929
Lead sponsor
PETHEMA Foundation
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Nov 25, 2019
Primary completion
Nov 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Feb 18, 2022

Study contacts

Josep Maria Ribera, Ph
Contact
jribera@iconcologia.net
934978987

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion